Moderna Reports $12 Billion Profit

mRNA pioneer Moderna has reported total revenue of $18.5 billion for the full year 2021, compared to $803 million in 2020. Product sales were $17.7 billion from sales of 807 million doses of the company’s Spikevax COVID-19 vaccine. Net income for 2021 was $12.2 billion, compared to a net loss of $747 million in 2020.

According to CEO Stéphane Bancel, “Spikevax is now approved in more than 70 countries around the world protecting hundreds of millions of people and real-world evidence from multiple independent studies has confirmed its strong effectiveness…Moderna has experienced exponential growth and we have more than doubled the size of our team over the last year with a global team of 3,000. We also have announced plans to scale to 21 commercial subsidiaries across the world, including four new locations in Asia and six new locations in Europe. We continue to expand and advance our industry-leading mRNA pipeline with 44 programs in development. We look forward to clinical readouts from our therapeutics development candidates later in 2022 in rare genetic diseases and oncology…”

In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of mRNA, to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing.

Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. (Source: Moderna Website, 24 February, 2022)